Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Sells $4,730,136.75 in Stock

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) Director G. Walmsley Graham sold 700,761 shares of the stock in a transaction that occurred on Tuesday, December 17th. The stock was sold at an average price of $6.75, for a total value of $4,730,136.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Olema Pharmaceuticals Trading Down 4.7 %

Shares of OLMA stock traded down $0.30 during trading hours on Tuesday, reaching $6.14. 1,361,945 shares of the company's stock were exchanged, compared to its average volume of 761,553. Olema Pharmaceuticals, Inc. has a fifty-two week low of $6.08 and a fifty-two week high of $16.77. The stock's 50 day moving average is $10.50 and its 200-day moving average is $11.85. The company has a market cap of $351.82 million, a price-to-earnings ratio of -2.80 and a beta of 1.92.

Hedge Funds Weigh In On Olema Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in OLMA. Hennion & Walsh Asset Management Inc. acquired a new position in Olema Pharmaceuticals during the second quarter valued at $945,000. Bank of New York Mellon Corp grew its position in Olema Pharmaceuticals by 72.1% during the second quarter. Bank of New York Mellon Corp now owns 139,923 shares of the company's stock valued at $1,514,000 after buying an additional 58,622 shares during the period. Rhumbline Advisers increased its holdings in Olema Pharmaceuticals by 43.5% in the second quarter. Rhumbline Advisers now owns 59,261 shares of the company's stock valued at $641,000 after buying an additional 17,953 shares in the last quarter. Victory Capital Management Inc. boosted its stake in shares of Olema Pharmaceuticals by 26.9% during the 2nd quarter. Victory Capital Management Inc. now owns 774,792 shares of the company's stock worth $8,383,000 after acquiring an additional 164,143 shares in the last quarter. Finally, Candriam S.C.A. grew its position in shares of Olema Pharmaceuticals by 199.9% during the 2nd quarter. Candriam S.C.A. now owns 1,058,673 shares of the company's stock valued at $11,454,000 after acquiring an additional 705,655 shares during the period. Hedge funds and other institutional investors own 91.78% of the company's stock.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a "buy" rating and issued a $30.00 price target on shares of Olema Pharmaceuticals in a research report on Wednesday, December 11th. Six analysts have rated the stock with a buy rating, According to MarketBeat, Olema Pharmaceuticals has a consensus rating of "Buy" and a consensus target price of $27.00.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.